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Abstract. Dichloroacetate (DCA) can reverse the glycolytic 
phenotype that is responsible of increased lactate production 
and extracellular pH acidification in cancer cells. Magnetic 
resonance imaging-chemical exchange saturation transfer 
(MRI-CEST) pH mapping is a novel non-invasive imaging 
approach that can measure in vivo extracellular tumour pH. 
We examined whether MRI-CEST pH mapping can monitor 
in vivo changes in tumour acidosis for assessing treatment 
response to DCA. Cell viability and extracellular pH were 
assessed in TS/A breast cancer cells treated with 1-10 mM 
DCA for 24 h in normoxia or hypoxia (1% O2) conditions. 
Extracellular tumour pH values were measured in vivo by 
MRI-CEST pH mapping of TS/A tumour-bearing mice before, 
three days and fifteen days after DCA or saline treatment. 
Reduced extracellular acidification and vitality was observed 
in DCA-treated TS/A cells. Tumour-bearing mice showed 
a marked and significant increase of tumour extracellular 
pH at 3 days post-DCA treatment, reflecting DCA-induced 
glycolysis inhibition, as confirmed by reduced lactate produc-
tion. After 15 days of DCA treatment, the onset of resistance 
to DCA was observed, with recover of tumour extracellular 
acidification and lactate levels that returned to baseline values. 
A significant correlation was observed between tumour extra-
cellular pH values and lactate levels (r= -0.97, P<0.05). These 
results suggest that MRI-CEST pH imaging appears to be a 
promising tool to monitor the early response and efficacy of 
cancer metabolic targeting drugs.
Introduction
It is well known that the extracellular pH (pHe) within the 
microenvironment of tumours is significantly lower (more 
acidic) compared with that of normal tissues (1). Although 
several factors play a role in the acidification process, it is 
well accepted that the major contribution arises from a shift in 
the ATP generation; according to the Warburg effect, ATP is 
produced via aerobic glycolysis even in presence of oxygen (2). 
In this contest, poor vascularisation and increased activity of 
plasma membrane ion pumps and transporters (H+-ATPases, 
the Na+-H+ exchanger NHE1 and the monocarboxylate-
H+ efflux co-transporters MCT1 and MCT4) contribute to 
the extracellular acidification of most, but not all tumours (3). 
Many studies on solid tumours and in particular on breast 
tumours suggested that a glycolytic environment is related 
not only to uncontrolled proliferation and evasion of apoptosis 
induction, but also to the expansion through the extra-cellular 
matrix, the increase of the metastatic potential and the promo-
tion of angiogenesis (4). Therefore, novel drugs addressing 
specific aspects of the deregulated tumour metabolism have 
been proposed for inhibiting tumour growth and survival.
Dichloroacetate (DCA), a mitochondria-targeting small 
molecule of 150 Da used to treat lactic acidosis, can reverse this 
cancer-specific metabolic remodelling (5). DCA inhibits pyru-
vate dehydrogenase kinase (PDK) whose expression is high 
in many cancers, causing pyruvate conversion into lactate (6). 
DCA-mediated inhibition of PDK re-establishes metabolism 
of pyruvate into the tricarboxylic acid cycle and decreases the 
lactate accumulation and production. Thus, DCA increases 
the glucose oxidation by promoting apoptosis and blocking 
tumour proliferation (7,8). Several clinical studies tested 
the DCA antitumour efficacy and its safety in patients with 
advanced solid tumours (9). Overall, these studies reported 
that oral DCA is well tolerated and safe, it reduces lactate 
levels and it can act as an apoptosis sensitizer in combination 
with cytotoxic treatments.
Despite the specific mechanism of action of DCA on tumour 
glycolysis, tumour response to DCA treatment has convention-
ally been assessed through simple measurements of changes in 
tumour size by using morphological imaging techniques such 
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as magnetic resonance imaging (MRI) or computed tomog-
raphy (CT). However, the assessment of changes in tumour 
volume does not provide indications on tumour acidosis varia-
tions induced by metabolism-targeting drugs. Several MRI 
methods have been proposed for non-invasive measurements of 
in vivo tumour pH (10). In particular, 31P-magnetic resonance 
spectroscopy (31P-MRS) allows measuring intracellular and 
extracellular pH changes from the chemical shift of endogenous 
phosphate or of exogenous agents, but with poor spatial resolu-
tion (11). gd-based contrast agents that exhibit a pH-dependent 
relaxivity have been exploited for measuring tumour pH in a 
rat glioma model, but a limitation of this approach is related 
to the need of injecting two Gd-based contrast agents for accu-
rate pH measurements (12). Hyperpolarized 13C-bicarbonate 
can provide pHe map with high sensitivity (13), while several 
hyperpolarised molecules can provide insight into metabolism 
in both cells and animals (14-18). However, this technique 
is expensive, limited by low spatial resolution and requires 
sophisticated instrumentations that are not easily available in 
the clinical setting.
Recently, chemical exchange saturation transfer (CEST) 
imaging has been proposed as a novel MRI-based technique 
and several agents have been considered for assessing tumour 
metabolism and pHe (19-23). Among them, clinical approved 
radiographic contrast agents and heterocyclic compounds 
have been exploited for measuring pH and pathological-
induced pH changes (24-28). In addition, MRI-CEST pH 
mapping was demonstrated to be an excellent tool to inves-
tigate the relationship between glycolysis and acidosis at 
clinical magnetic field (29).
In this study, we investigated whether DCA-induced 
changes in metabolism and tumour acidosis in a murine breast 
cancer model can be monitored non-invasively by MRI-CEST 
pH mapping.
Materials and methods
Cell culture. TS/A cells, derived from a spontaneous BALB/c 
mammary tumour, were grown in RPMI-1640 medium 
supplemented with 10% fetal bovine serum (fBS), 100 U/ml 
penicillin and 100 µg/ml streptomycin (Pen/Strep) and 2 mM 
L-glutamine (30). 4T1 cells, a BALB/c-derived mouse 
mammary carcinoma corresponding to stage Iv of human 
breast cancer, were purchased from American Type Culture 
Collection, ATCC and cultured as TS/A cells. TUBO cells 
were derived from a lobular carcinoma arising spontaneously 
in a BALB-neuT mouse and were grown in DMEM medium 
supplemented with 20% fBS and Pen/Strep (31).
J774 non-tumour cell line (purchased from ATCC) was 
grown in DMEM medium supplemented with 10% fBS, 
Pen/Strep and L-glutamine. All the cell lines were cultured in 
a humidified atmosphere (37˚C, 5% CO2).
Cell vitality test. The cytotoxic effect of DCA (Sigma-Aldrich, 
St. Louis, MO, USA) on cells was analysed with the CellTiter-
Blue Cell viability Assay (Promega Corp., Madison, WI, 
USA). Briefly, TS/A (5x103) cells were plated in 96-well culture 
plates and after 24 h of incubation were treated with DCA (1, 5 
and 10 mM) for 24 h. The non-tumour cell line J774 (30x103) 
was used as control and treated in the same way. Afterwards, 
cells were washed with PBS and then CellTiter-Blue reagent 
was added to each well. fluorescence was measured at 
560Ex/590Em using a 96-well plate reader. Each assay was 
repeated at least three times.
pH measurement in normoxia and hypoxia condition. TS/A 
cells were seeded in 60-mm culture dish with a final volume 
of 3 ml at a density of 4x105 cells. After 24 h of incubation in 
20% O2 (normoxia) or 1% O2 (hypoxia) (New Brunswick™ 
Galaxy® 48 R, Eppendorf S.r.l., Milan, Italy) cells were 
treated with a solution of DCA (1, 5 and 10 mM) and kept 
in the culture medium for additional 24 h. Then the culture 
medium was collected and the pH was immediately measured 
using a pH meter (Hamilton® Slim Trode, gR, Switzerland) 
previously calibrated. The non-tumour cell line J774 under-
went the same procedure. Each experiment was performed 
in triplicate.
FACS analysis. The cell cycle perturbations were analysed 
by propidium iodide (PI) DNA staining. TS/A cells (5x105) 
were treated with DCA (1, 5 and 10 mM) for 24 h. At the 
end of each treatment, cells were collected after a centrifuga-
tion (200 x g, 5 min) and then fixed in ethanol (70%, 3 min, 
4˚C). Ethanol-suspended cells were diluted with phosphate 
buffered saline (PBS) and then centrifuged to remove residual 
ethanol (471 x g, 5 min). for cell cycle analysis, the pellets 
were suspended in 0.1 ml of PBS containing 50 µg/ml of PI, 
100 µg/ml of RNase A and 0.05% of Triton X-100 and incu-
bated at 37˚C for 40 minutes. Cell cycle profiles were studied 
using a CyanADP flow cytometer and analysed with Summit 
3.4 software (Beckman Coulter) and BD fACSuite software 
(Becton Dickinson). Each assay was repeated a minimum of 
three times.
Animal experiments. BALB/c female mice (Charles River 
Laboratories Italia S.r.l., Calco, Italy) were maintained in 
the animal facility of the Dept. Molecular Biotechnology 
and Health Sciences, University of Turin, under specific 
pathogen-free conditions. All animal studies were approved 
by the University Ethics Committee in accordance with the 
European guidelines under directive 2010/63.
Mice were inoculated subcutaneously with 2.5x105 TS/A 
mammary adenocarcinoma cells on both flanks. When the 
tumours were approximately 60 mm3, TS/A tumour-bearing 
mice were randomly divided in two groups: untreated group 
that received drinking water and intraperitoneal injections 
of PBS, and DCA-treated group that received DCA by oral 
administration of 0.45 g/l (100 mg/kg/day) and also by intra-
peritoneal injections of 50 g/l (200 mg/kg/day) (32). DCA 
or PBS solutions were administered every day after baseline 
measurements. All mice were scanned at day 0 (untreated 
n=10 mice, treated n=8 mice), 3 days (untreated n=10 mice, 
treated n=8 mice) and 15 days (untreated n=7 mice, treated 
n=5 mice) post-treatment. At each time point post-treatment, 
three mice per group were sacrificed and tumour tissues were 
excised for lactate level quantification.
for MRI acquisition mice were anesthetized and the breath 
rate was monitored by an air pillow placed below the animal 
(SA Instruments, Stony Brook, Ny, USA). MRI-CEST pH 
mapping was performed upon i.v. injection of 4 g I/kg b.w. 
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iopamidol (Bracco Imaging SpA, Colleretto giacosa, Italy) 
into the tail vein through a 27-gauge needle.
MRI CEST pH-mapping acquisition and analysis. MR images 
were acquired with a Bruker 7T Avance 300 MRI scanner 
(Bruker Biospin, Ettlingen, germany) equipped with a 30-mm 
1H birdcage coil before starting the treatment, after 3 and 
15 days of treatment.
Anatomical T2w images were acquired with a fast Spin 
Echo (fSE) sequence and the same geometry was used for 
the following CEST experiments. CEST images were acquired 
before and after iopamidol i.v. injection with a single shot fSE 
sequence with centric encoding preceded by a continuous-
wave saturation pulse (power: 3 µT, duration: 5 sec) on a central 
tumour slice (field-of-view: 3 cm, matrix: 128x128, in-plane 
resolution: 234 µm, slice thickness: 1.5 mm). CEST images 
were analysed using homemade MATLAB scripts (Mathworks, 
Inc., Natick, MA, USA). Briefly, saturation transfer effects were 
calculated upon irradiating at 4.2 and at 5.5 ppm, respectively, 
and post-contrast ST maps were subtracted to pre-contrast ST 
ones, to obtain the corresponding ST contrast difference (∆ST) 
maps. The pixel-by-pixel extracellular pH (pHe) maps were 
calculated using the ratio between the two contrast difference 
maps at 4.2 and 5.5 ppm according to the previously described 
method (24). The calculated pHe maps were superimposed to 
the anatomical reference image.
A novel estimate, dubbed acidity score, was calculated for 
taking into account the heterogeneity of pHe distribution values 
within the tumour region. The tumour pixels were clustered 
into three groups: group I for pixels showing pHe values >7.0, 
group II for pixels showing pHe values >6.7 and <7.0, group III 
for pixels showing pHe values <6.7. The percentage of pixels 
of each group was multiplied by a factor between 1 and 3, to 
obtain the acidity score, in accordance to the equation:
The acidity score ranges from 1 (less acidic) to 3 (more acidic), 
describing tumour regions with different acidosis levels.
Survival curves. A second cohort of female BALB/c mice 
were inoculated with 2.5x105 TS/A cells into the right flank for 
long-term effect following DCA treatment. After the tumour 
reached 1 mm mean diameter, animals were randomized into 
two groups: untreated (n=9 mice) and DCA-treated (n=11 
mice). DCA-treated group received DCA by oral administra-
tion (100 mg/kg/day) and also by intraperitoneal injection 
(200 mg/kg/day) every day. Untreated group received equal 
volumes of PBS. Mice were monitored every day and volumes 
were measured using a calliper and calculated from orthogonal 
measurements of external dimensions as (width2 x length)/2. 
Mice were euthanized when tumour volume reached values 
around 600 mm3.
Lactate assay. TS/A cells were seeded in 60-mm culture dish 
with a final volume of 3 ml and incubated under standard cell 
culture condition overnight for 24 h. Thereafter, cells were 
treated with DCA for 24 h and culture media was collected 
and tested for lactate level following the manufacturer's 
instructions of Lactate assay kit (MAK064 Sigma-Aldrich).
After MRI acquisition, three mice per each time point 
and group were sacrificed and tumour tissues were excised 
and frozen in liquid nitrogen. Tumour tissue was explanted 
after animal sacrifice and it was frozen in liquid nitrogen. 
Tumour was then homogenized on ice in 4 volumes of lactate 
assay buffer; the sample was centrifuged at 13.000 x g for 
10 min to remove insoluble material and deproteinized with 
a 10 kDa MWCO spin filter to remove endogenous lactate 
dehydrogenase. The soluble fraction was then assayed by 
Lactate assay kit.
Statistical analysis. Calculations were performed using 
graphPad Prism (graphPad Software, La Jolla, CA, USA) 
software package. Significance between DCA-treated and 
figure 1. In vitro efficacy of DCA on breast cancer cell lines. Percentage of vitality of TS/A cultured in normoxic (A) and hypoxic condition (f), and of 4T1 (B), 
TUBO (C) and non-tumour control cell line J774 (D) cells after 24 h of DCA treatment in normoxic condition. Culture medium extracellular lactate levels in 
normoxic conditions for TS/A, 4T1 and TUBO (E).  *P<0.05; **P<0.01; ***P<0.001, Dunnett's multiple comparison test.
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control groups was determined by one-way analysis of vari-
ance, followed by post-hoc tests with the Dunnett's multiple 
comparison test. Correlation analysis was performed using 
Pearson's r correlation coefficient. Data are presented as 
mean ± SD unless otherwise stated. Statistical significance 
was established at P<0.05.
Results
DCA metabolic inhibition impairs TS/A proliferation but not 
the cell cycle. In order to investigate the metabolic inhibi-
tion efficiency of DCA, a panel of breast cancer cell lines 
was treated with several concentrations of DCA for 24 h 
under normoxia condition. As shown in fig. 1, after 24 h of 
treatment, TS/A, 4T1 and TUBO cancer cell lines showed a 
reduction in their metabolic capacity even at low concentra-
tion, whereas the non-tumour J774 control cell line was not 
affected (fig. 1D). The response of TS/A breast cancer after 
24 h of DCA treatment was dose-dependent (fig. 1A) and a 
significant reduction of cell vitality was already observed at 
5 mM DCA concentration.
Furthermore, compared to the other cell lines, untreated 
TS/A cells produced significantly higher level of lactate 
(fig. 1E), hence reflecting a more glycolytic phenotype that 
could explain their higher sensitivity to DCA treatment. On 
the basis of these observations, TS/A cell line was selected for 
subsequent in vitro and in vivo studies.
DCA effect was also investigated under hypoxia (1% O2) 
to mimic in vivo tumour hypoxic conditions. A significant 
decrease in TS/A vitality was observed for all the investigated 
DCA concentrations, compared to untreated cells (fig. 1f).
In order to verify if the effect exerted by DCA on cancer 
cell vitality was due to a perturbation of their cell cycle, as 
reported for glioblastoma, glioma, non-small cell lung cancer 
and other cancer cell lines (33-36), TS/A cells were incubated 
with DCA for 24 h, then stained with PI and analysed by flow 
cytometry. As shown in the graph (fig. 2D) and in the repre-
sentative histograms reported in fig. 2E, DCA did not affect 
the cell cycle of TS/A cells, although the amount of cells in the 
g1/g0 phase decreased from 51.6% (untreated cells) to 45.9% 
in the presence of 10 mM DCA while cells in g2/M phase 
increased from 18.8% (untreated cells) to 23.1%. The amount 
of TS/A cells in the S phase did not change between untreated 
and treated with 10 mM of DCA. Moreover, the percentage 
of hypodiploid cells undergoing apoptosis-induced DNA 
fragmentation, represented by the sub-g1/g0 population, was 
very low in all the conditions analysed, and was not increased 
by DCA treatment. These data suggest that DCA can affect 
cell vitality through different mechanisms in different types of 
tumours, mainly acting as a metabolic agent.
DCA promotes extracellular pH alkalinisation in both 
normoxia and hypoxia conditions. Treatment of TS/A cells for 
24 h in normoxic condition (fig. 2A) resulted in a moderate 
but significant and constant increase of culture medium pH 
values (from 7.06±0.02 to 7.23±0.01) with increasing DCA 
concentrations. The increase of pHe was significantly more 
pronounced in the hypoxic condition (fig. 3A) than in the 
normoxic condition. In fact, hypoxic condition resulted in 
lower pH of the culture medium for untreated TS/A cells 
in comparison to normoxic condition (pHe = 6.78±0.02). 
Moreover, DCA treatment resulted in an even higher increase 
of pHe up to 7.53±0.01 (P<0.001). The measured increase 
in extracellular pH displayed by TS/A cells after treatment 
is linked to the DCA-induced switch from glycolytic to 
more oxidative phenotype as evidenced by decreased lactate 
levels measured in the extracellular medium of TS/A cells. 
In particular, we observed a significant decrease in lactate 
figure 2. In vitro efficacy of DCA on TS/A acidification and cell cycle progression. Culture medium pH measurements after 24 h of DCA treatment for 
TS/A cells grown in normoxic (20% O2, A) conditions. Culture medium extracellular lactate level measurement after 24 h of DCA treatment for TS/A cells 
grown in normoxic (20% O2, B) conditions. Correlation between changes in lactate levels and extracellular pH measured in the culture medium (Pearson's 
r= -0.98, P<0.05, C). (D and E) Cell cycle distribution of TS/A cells treated with different doses of DCA for 24 h analyzed by flow cytometry after propidium 
iodide staining. (D) Bar graph showing the percentage of cells in the different phases of cell cycle (from three independent experiments, mean ± SEM) and 
(E) representative flow cytometer histograms. *P<0.05; **P<0.01; ***P<0.001, Dunnett's multiple comparison test.
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production following DCA treatment in both normoxic and 
hypoxic conditions (figs. 2B and 3B). Moreover, the in vitro 
anti-glycolytic effect of DCA revealed a strong and signifi-
cant correlation between pH and lactate changes in normoxic 
condition (r= -0.98, P=<0.05, fig. 2C), likely reflecting the 
impaired glycolytic activity that results in a reduced lactate 
production, hence acidification. A strong correlation was also 
found for cells treated in hypoxic condition even although 
not statistically significant (r= -0.93, P=0.07, fig. 3C). Taken 
together, these data confirmed the in vitro reversal of the 
glycolytic phenotype following DCA treatment.
DCA does not influence tumour growth and survival. The 
in vivo antitumour activity of DCA was evaluated by measuring 
tumour growth in a group of TS/A tumour-bearing BALB/c 
mice that received drinking water and PBS intraperitoneal 
injection (untreated) or that were treated with DCA by oral 
administration and intraperitoneal injection every day for 3 or 
15 consecutive days (fig. 4A). DCA treatment slightly reduced 
the growth of TS/A breast tumours after three days of treat-
ment (∆volume% = 70.7±38.6 and 83.1±15.7, for treated and 
untreated mice, respectively; P>0.05). This limited growth 
reduction is maintained up to 15 days of DCA treatment 
(∆volume% = 571.9±180.7 and 646.7±184.0, for untreated and 
treated mice, respectively; P>0.05) (fig. 4B).
The survival study conducted in another group of mice 
revealed that DCA-treated mice survived slightly longer than 
the untreated mice (fig. 4C), despite this difference not being 
statistically significant. These data suggest that DCA did not 
influence tumour growth and did not improve mouse survival 
for the TS/A tumour model.
DCA affects in vivo tumour acidosis and lactate production. 
A significant pHe increase was observed for treated mice 
in comparison to untreated ones after three days of DCA 
treatment (∆pHe = +0.10±0.03 and -0.12±0.03 for treated 
and untreated, respectively, P<0.05, fig. 5A). The same pHe 
variations were maintained also after 15 days of treatment, 
figure 3. In vitro efficacy of DCA on TS/A acidification in hypoxic condition. Culture medium pH measurements after 24 h of DCA treatment for TS/A cells 
grown in hypoxic (1% O2, A) conditions. Culture medium extracellular lactate level measurement after 24 h of DCA treatment for TS/A cells grown in hypoxic 
(1% O2, B) conditions. Correlation between changes in lactate levels and extracellular pH measured in the culture medium (Pearson's r= -0.93, P=0.07, C). 
*P<0.05; **P<0.01; ***P<0.001, Dunnett's multiple comparison test.
figure 4. Effect of DCA on tumour growth in vivo. (A) Normalised and (B) percentage changes in volume (∆volume%) of TS/A tumour-bearing mice before 
and after 3 or 15 days of DCA treatment. (C) Mouse survival curve after DCA treatment.
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despite less marked (∆pHe= +0.004±0.04 and -0.09±0.04 for 
treated and untreated, respectively, fig. 5A). Representative 
MRI-CEST pHe images over imposed to anatomical images 
are shown in fig. 6 for untreated (fig. 6A) and treated (fig. 6B) 
mice. following DCA-treatment, an increase of the number of 
pixels with more neutral pHe values is visible, in contrast to 
untreated mice at both the investigated time points (i.e. after 
3 and 15 days of DCA treatment).
To assess more precisely the heterogeneity of the extra-
cellular pH distribution inside the tumour region, it was 
deemed of interest to calculate the acidity score as an index 
of spatial distribution of acidosis. A marked and statistically 
significant difference was observed in the changes of the 
acidity scores between untreated and treated mice after 3 days 
of treatment (∆acidity score = -0.14±0.23 and +0.15±0.34, 
P<0.05, fig. 5B). After 15 days a marked difference in pHe 
distribution still remains between treated and untreated mice 
(∆acidity score = +0.003±0.24 and +0.18±0.35 for treated and 
untreated mice, respectively; P>0.05). Representative acidity 
score maps are shown in fig. 6C and D for untreated and 
treated mice. Upon DCA-treatment, a decrease in the number 
of pixels clustered at more acidic pH values (colour coded 
in red) is well detected after three days of treatment. The 
MRI-based measurements of tumour extracellular pH showed 
that DCA was effective in inhibiting tumour glycolysis in vivo, 
resulting in a marked decreased acidification of the interstitial 
space, as observed for the in vitro studies.
Tumour lactate concentration of treated mice was signifi-
cantly decreased compared with untreated ones (lactate levels 
in treated mice was ca. three times lower than in untreated 
mice, P=0.0077). No significant variation in tumour lactate 
levels was observed comparing treated to untreated mice after 
15 days (fig. 5C). A strong and significant inverse correlation 
was found between lactate levels and changes in tumour pHe 
(r= -0.97, P<0.05, fig. 5D). These results suggest that DCA 
can inhibit the glycolytic activity of TS/A tumours, at least for 
early time points and that changes in lactate production and 
extracellular pH are highly correlated.
Discussion
High rate of glucose uptake and of lactate production are two 
distinctive features of metabolically altered tumour cells. 
DCA is able to revert the glycolytic phenotype through meta-
bolic inhibition of PDK that allows pyruvate to enter into the 
tricarboxylic acid cycle thus limiting lactate production and in 
turn, decreasing H+ ions pumped out in the extracellular space. 
Herein, we investigated the effect of DCA on tumour pHe in a 
breast cancer murine model using a non-invasive MRI-based 
CEST pH imaging approach.
All the investigated breast cancer cell lines showed a 
marked reduction in their metabolic capacity and vitality, but 
their response to DCA was dependent on DCA concentration 
as well as on the cell line itself, hence indicating different 
sensitivity. Previous studies in other breast cancer cell lines 
showed that they were sensitive to DCA (32) but not all to the 
same extent, indicating a cell line dependency. Sensitivity to 
DCA may be dependent on several factors, including different 
expression and/or activity of PDK-PDH isoenzymes (37), or 
DCA internalization that is dependent on the ability to reach 
mitochondria matrix (38).
Moreover, evidence confirmed that the DCA effect on cell 
cycle is also cellular-dependent and studies conducted on glio-
blastoma, glioma, non-small cell lung cancer and colon rectal 
cancer cells revealed that DCA treatment at 20 mM concentra-
tion caused apoptosis and g2 phase cell cycle arrest (33,34). 
In TS/A cells, 10 mM DCA induced a small increase in g2/M 
phase although not statistically significant. Taken together 
figure 5. Effect of DCA on extracellular tumour pH (pHe) and on lactate levels in vivo. Tumour pHe (A) and acidity score (B) changes calculated from 
TS/A tumour-bearing mice upon DCA treatment after 3 and 15 days, in comparison to before treatment tumour pHe values for untreated and treated mice. 
(C) Lactate quantification from excised TS/A tumour tissues for untreated and treated mice after 3 and 15 days of DCA treatment. (D) Correlation between 
changes in tumour pHe and lactate levels (Pearson's r= -0.97, *P<0.05).
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these data indicate that DCA is not a cytotoxic drug but it acts 
as a metabolic agent.
DCA-induced glycolysis inhibition is expected to reduce 
lactate production, hence alter extracellular acidification, as 
already demonstrated in previous in vitro studies by measuring 
pHe changes (39,40). Within this study, we observed a marked 
increase of extracellular pH that was dependent on DCA 
concentration; moreover, the alkalinisation of pHe was even 
more pronounced when TS/A cells were cultured in hypoxic 
conditions (1% O2) than in normoxic conditions, simulating 
a poorly-perfused tumour microenvironment. Our in vivo 
MRI-based observations reflect similar findings, since we 
measured a significant increase in tumour pHe as early as 
three days after DCA-treatment.
Other studies in breast and prostate cell lines showed that 
lactate production is reduced upon DCA treatment (41-43). We 
observed that lactate production was reduced following DCA 
treatment both in vitro, just after 24 h, as well as in vivo, with a 
marked decrease in lactate levels after three days of treatment. 
Notably, these changes in lactate levels were highly correlated 
with changes in pHe in vitro and the same strong correlation 
was found in vivo, likely reflecting the intertwined depen-
dence between glycolysis, lactate levels and tumour acidosis 
(figs. 2C, 3C and 5D).
figure 6. Representative tumour extracellular pH (pHe, reflecting acidosis) maps for untreated (A) and treated mouse (B) and their corresponding acidity score 
maps (color-coded as red for pixels showing pH values <6.7; green for pH values >6.7 and <7; blue for pH values >7.0) for untreated (C) and treated mouse (D) 
superimposed on anatomical images at baseline (left), 3 days (middle) and 15 days (right) post-DCA treatment. Tumour pHe and acidity score values are shown 
only within tumour regions for improving clarity.
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Although other in vivo studies confirmed the DCA anti-
tumour activity on solid tumours (44), in this study treated 
mice showed a limited tumour growth reduction following 
15 days of treatment and only a slight increase of the survival 
time was observed as compared to untreated mice. This may 
be explained considering that DCA alone has a moderate 
efficiency as chemotherapeutic drug, and its antineoplastic 
pharmacological effect can be augmented when used in 
combination with other drugs (41,45,46). Our results are in 
agreement with these observations, as similar lactate levels 
were observed in untreated and treated mice after 15 days of 
treatment. These results parallel those obtained by measuring 
in vivo tumour pHe, which at 15 days show a reduced difference 
between treated and untreated mice in terms of pHe changes 
and of acidity scores. These findings confirm the ability of 
the proposed non-invasive approach to assess the onset of 
resistance to DCA, since tumour acidosis returned to almost 
baseline values after 15 days. This behaviour was confirmed 
by similar changes in lactate levels. Moreover, the inefficacy 
of DCA to halt tumour glycolysis after 15 days, as measured 
by the proposed approach, anticipated the lack of difference in 
terms of survival times between treated and untreated groups.
In this study, in vivo pH changes were assessed by 
MRI-CEST imaging using iopamidol, an MRI-CEST 
pH-responsive agent able to map pHe and tumour perfusion 
in the microenvironment in which it is distributed (47-49). 
Although iopamidol showed a heterogeneous distribution in 
the tumour region, the application of the ratiometric pH method 
allowed obtaining representative pH maps for the region of 
interest. To get more insight into the tumour pHe heterogeneity, 
we calculated the acidity score that reports on the distribution 
of pixels clustered on the basis of their relative acidity inside 
the tumour region. Representative acidity score maps showed 
an increase in blue pixels during DCA treatment for treated 
mice (fig. 6D), reflecting the DCA-induced glycolysis inhibi-
tion, hence alkalinisation of tumour pHe, although we cannot 
exclude that there are other pathways that may contribute to 
tumour extracellular acidification (50). A similar decrease of 
tumour acidosis was observed in a xenograft model of B-cell 
lymphoma upon treatment with metaiodobenzylguanidine by 
using an analogous pH-responsive CEST agent (51). Of note, 
also endogenous CEST pH mapping allowed monitoring 
intracellular acidification following lonidamine or topiramate 
treatment in orthotopic glyoblastoma tumours (52,53). All 
these results confirm the feasibility of MRI-CEST pH mapping 
to monitor the response to drugs targeting tumour metabolism.
In conclusion, despite the lack of tumour growth reduction, 
this study demonstrated that MRI-CEST pH imaging is able 
to detect the early response to DCA by measuring changes in 
tumour pHe. These findings correlated well with the observed 
reduced lactate levels as a consequence of the reversed 
glycolytic phenotype. These results suggest that MRI-CEST 
pH imaging may serve as a useful imaging biomarker for 
monitoring changes in metabolism following drugs targeting 
tumour deregulated glycolysis.
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